Induction chemotherapy for head and neck cancer: Will history repeat itself?

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 3, Issue 3, 2005, Pages 393-403

  Argiris, Athanassios ^a,b,c  

^a University of Pittsburgh ^*

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Chemoradiotherapy; Head and neck cancers; Induction chemotherapy; Squamous cell cancer; Systemic cancer therapies

Indexed keywords

CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; FLUOROURACIL; FOLINIC ACID; IFOSFAMIDE; PACLITAXEL; PLATINUM DERIVATIVE; ANTINEOPLASTIC AGENT;

AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL PRACTICE; CLINICAL TRIAL; DIARRHEA; DISEASE CONTROL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG SCREENING; FEBRILE NEUTROPENIA; HEAD AND NECK CANCER; HUMAN; INFECTION; KIDNEY DISEASE; MUCOSA INFLAMMATION; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; STOMATITIS; TOXICITY; VOMITING; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; CANCER STAGING; HEAD AND NECK TUMOR; PATHOLOGY; RADIOTHERAPY; REVIEW; SQUAMOUS CELL CARCINOMA;

ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; HEAD AND NECK NEOPLASMS; HUMANS; NEOADJUVANT THERAPY; NEOPLASM STAGING; RADIOTHERAPY;

EID: 24944483456     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2005.0020     Document Type: Article

References (61)

1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin 2004;54:8-29.
2. Kramer S, Gelber RD, Snow JB, et al. Combined radiation therapy and surgery in the management of advanced head and neck cancer: final report of study 73-03 of the Radiation Therapy Oncology Group. Head Neck Surg 1987;10:19-30.
3. Taylor SGT. Why has so much chemotherapy done so little in head and neck cancer? J Clin Oncol 1987;5:1-3.
4. Rosenthal DI, Pistenmaa DA, Glatstein E. A review of neoadjuvant chemotherapy for head and neck cancer: partially shrunken tumors may be both leaner and meaner. Int J Radiat Oncol Biol Phys 1994;28:315-320.
5. Argiris A. Update on chemoradiotherapy for head and neck cancer. Curr Opin Oncol 2002;14:323-329.
6. Argiris A, Jayaram P, Pichardo D. Revisiting induction chemotherapy for head and neck cancer. Oncology 2005, 19 (in press).
7. Hitt R, Lopez-Pousa A, Rodriguez M, et al. Phase III study comparing cisplatin (P) & 5-fluoruracil (F) versus P, F and paclitaxel (T) as induction therapy in locally advanced head & neck cancer (LAHNC) (Abstr). Proc Am Soc Clin Oncol 2003;22:A1997.
8. Vermerken JB, Remenar E, Van Herpen C, et al. Standard cisplatin/infusional 5-fluorouracil (PF) vsdocetaxel (T) plus PF (TPF) as neoadjuvant chemotherapy for nonresectable locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN): a phase III trial of the EORTC Head and Neck Cancer Group (EORTC #24971) (Abstr). Proc Am Soc Clin Oncol 2004;22:A5508.
9. Kish J, Drelichman A, Jacobs J, et al. Clinical trial of cisplatin and 5-FU infusion as initial treatment for advanced squamous cell carcinoma of the head and neck. Cancer Treat Rep 1982;66:471-474.
10. Nadeem A, Desai S, Chougule P, et al. Decreased distant recurrence and preserved local control using dose dense induction weekly paclitaxel (P) and carboplatin (C) followed by concurrent paclitaxel, carboplatin and radiotherapy (CRT) in locally advanced head and neck squamous cell cancers (HN-SCC) (Abstr). Proc Am Soc Clin Oncol 2004;22:A5545.
11. Haraf DJ, Rosen FR, Stenson K, et al. Induction chemotherapy followed by concomitant TFHX chemoradiotherapy with reduced dose radiation in advanced head and neck cancer. Clin Cancer Res 2003;9:5936-5943.
12. Vokes EE, Stenson K, Rosen FR, et al. Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer. J Clin Oncol 2003;21:320-326.
13. Fornari G, Artusio E, Mairone L, et al. Paclitaxel and carboplatin in neo-adjuvant and concomitant chemoradiotherapy in locally advanced head and neck squamous cell carcinoma. Tumori 2002;88:489-494.
14. Cmelak A, Murphy BA, Burkey B, et al. Induction chemotherapy (IC) followed by concurrent chemoradiation (CCR) for organ preservation (OP) in locally advanced squamous head and neck cancer (SHNC): results of a Phase II trial (Abstr). Proc Am Soc Clin Oncol 2003;22:A2016.
15. Machtay M, Rosenthal DI, Hershock D, et al. Organ preservation therapy using induction plus concurrent chemoradiation for advanced resectable oropharyngeal carcinoma: a University of Pennsylvania Phase II Trial. J Clin Oncol 2002;20:3964-3971.
16. Dunphy FR, Dunleavy TL, Harrison BR, et al. Induction paclitaxel and carboplatin for patients with head and neck carcinoma. Analysis of 62 patients treated between 1994 and 1999. Cancer 2001;91:940-948.
17. Schoffski P, Catimel G, Planting AS, et al. Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a phase II study of the EORTC Early Clinical Studies Group. Ann Oncol 1999;10:119-122.
18. Mel JR, Rodriguez R, Constela M, et al. Phase II study of docetaxel and cisplatin as induction chemotherapy in locally advanced squamous cell cacinoma of the head and neck: preliminary results. Proc Am Soc Clin Oncol (Abstr) 1999;18:A1549.
19. Cruz JJ, Fonseca E, Garcia Gomez J, et al. Randomized phase II, multicenter trial of induction chemotherapy in patients with locally advanced head and neck carcinoma (LA-HNC). Docetaxel plus cisplatin (DP) versus cisplatin plus 5-FU (PF): interim results. Proc Am Soc Clin Oncol 2002;21:A920.
20. Hitt R, Paz-Ares L, Brandariz A, et al. Induction chemotherapy with paclitaxel, cisplatin and 5-fluorouracil for squamous cell carcinoma of the head and neck: long-term results of a phase II trial. Ann Oncol 2002;13:1665-1673.
21. Schrijvers D, Van Herpen C, Kerger J, et al. Docetaxel, cisplatin and 5-fluorouracil in patients with locally advanced unresectable head and neck cancer: a phase I-II feasibility study. Ann Oncol 2004;15:638-645.
22. Colevas AD, Norris CM, Tishler RB, et al. Phase I/II trial of outpatient docetaxel, cisplatin, 5-fluorouracil, leucovorin (opTPFL) as induction for squamous cell carcinoma of the head and neck (SCCHN). Am J Clin Oncol 2002;25:153-159.
23. Posner MR, Glisson B, Frenette G, et al. Multicenter phase I-II trial of docetaxel, cisplatin, and fluorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck. J Clin Oncol 2001;19:1096-1104.
24. Janinis J, Papadakou M, Panagos G, et al. Sequential chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil in patients with locally advanced head and neck cancer. Am J Clin Oncol 2001;24:227-231.
25. Colevas AD, Norris CM, Tishler RB, et al. Phase II trial of docetaxel, cisplatin, fluorouracil, and leucovorin as induction for squamous cell carcinoma of the head and neck. J Clin Oncol 1999;17:3503-3511.
26. Colevas AD, Busse PM, Norris CM, et al. Induction chemotherapy with docetaxel, cisplatin, fluorouracil, and leucovorin for squamous cell carcinoma of the head and neck: a phase I/II trial. J Clin Oncol 1998;16:1331-1339.
27. Posner MR, Lefebvre JL. Docetaxel induction therapy in locally advanced squamous cell carcinoma of the head and neck. Br J Cancer 2003;88:11-17.
28. Shin DM, Glisson BS, Khuri FR, et al. Phase II trial of paclitaxel, ifostamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma. J Clin Oncol 1998;16:1325-1330.
29. Shin DM, Khuri FR, Glisson BS, et al. Phase II study of paclitaxel, ifostamide, and carhoplatin in patients with recurrent or metastatic head and neck squamous cell carcinoma. Cancer 2001;91:1116-1323.
30. Shin DM, Glisson BS, Khuri FR, et al. Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carhoplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck. Cancer 2002;95:322-230.
31. Khuri F, Gillenwater A, Diaz E, et al. Pilot trial of paclitaxel, ifosfamide and cisplatin (TIP) as induction or exclusive therapy for intermediate to advanced laryngeal cancer (Abstr). Proc Am Soc Clin Oncol 2002;21:A906.
32. Kies MS, Lewin JS, Diaz EM, et al. Definitive treatment ot intermediate stage laryngeal squamous cell (SCC/L) cancer with chemotherapy (CT). Proc Am Soc Clin Oncol 2004;22:A5533.
33. Pignon JP, Bourhis J, Domenge C, et al. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 2000;355:949-955.
34. De Andres L, Brunet J, Lopez-Pousa A, et al. Randomized trial of neoadjuvant cisplatin and fluorouracil versus carboplatin and fluorouracil in patients with stage IV-M0 head and neck cancer. J Clin Oncol 1995;13:1493-1500.
35. Schuller DE, Stein DW, Metch B. Analysis of treatment failure patterns. A Southwest Oncology Group Study. Arch Otolaryngol Head Neck Surg 1989;115:834-836.
36. Paccagnella A, Orlando A, Marchiori C, et al. Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della Testa e del Collo. J Natl Cancer Inst 1994;86:265-272.
37. Domenge C, Hill C, Lefebvre JL, et al. Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. French Groupe d'Etude des Tumeurs de la Tete et du Cou (GETTEC). Br J Cancer 2000;83:1594-1598.
38. Lewin F, Damher L, Jonsson H, et al. Neoadjuvant chemotherapy with cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the head and neck: a randomized phase III study. Radiother Oncol 1997;43:23-28.
39. Dalley D, Beller E, Aroney R, et al. The value of chemotherapy (CT) prior to definitive local therapy (DLT) in patients with locally advanced squamous cell carcinoma (SCC) of the head and neck (HN) (Abstr). Proc Annu Meet Am Assoc Cancer Res 1995;14:A856.
40. Depondt J, Gehanno P, Martin M, et al. Neoadjuvant chemotherapy with carboplatin/5-fluorouracil in head and neck cancer. Oncology 1993;50(suppl 2):23-27.
41. Licitra L, Grandi C, Guzzo M, et al. Primary chemotherapy in resectable oral cavity squamous cell cancer: a randomized controlled trial. J Clin Oncol 2003;21:327-333.
42. Taylor SGt, Murthy AK, Vannetzel JM, et al. Randomized comparison of neoadjuvant cisplatin and fluorouracil infusion followed by radiation versus concomitant treatment in advanced head and neck cancer. J Clin Oncol 1994;12:385-395.
43. Adelstein D, Saxton J, Lavertu P, et al. A phase III randomized trial comparing concurrent chemotherapy (CT) and radiation therapy (RT) with RT alone in resectable stage III and IV squamous cell head and neck cancer (SCHNC): preliminary results, In: 4th International Conference on Head and Neck Cancer. Toronto, Canada, The Society of Head and Neck Surgeons and American Society of Head and Neck Surgery; 1996.
44. Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003;34:2091-2098.
45. Calais G, Alfonsi M, Bardet E, et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage orophaynx carcinoma. J Natl Cancer Inst 1999;91:2081-2086.
46. Al-Sarraf M, LeBlanc M, Giri P, et al. Superiority of chemoradiotherapy vs radiotherapy in patients with locally advanced nasopharyngeal cancer preliminary results of intergroup (0099) (SWOG 8892, RTOG 8817, ECOG 2388) randomized study (Abstr #882). Proc Am Soc Clin Oncol 1996;15:313.
47. Adelstein DJ, Li Y, Adams GL, et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 2003;21:92-98.
48. Al-Sarraf M, LeBlanc M, Giri PG, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol 1998;16:1310-1317.
49. Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004;350:1937-1944.
50. Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004;350:1945-1952.
51. Adelstein DJ, Saxton JP, Lavertu P, et al. Maximizing local control and organ preservation in stage IV squamous cell head and neck cancer With hyperfractionated radiation and concurrent chemotherapy. J Clin Oncol 2002;20:1405-1410.
52. Vokes EE, Kies MS, Haraf DJ, et al. Concomitant chemoradiotherapy as primary therapy for locoregionally advanced head and neck cancer. J Clin Oncol 2000;18:1652-1661.
53. Argiris A, Haraf DJ, Kies MS, et al. Intensive concurrent chemoradiotherapy for head and neck cancer with 5-fluorouracil- and hydroxyurea-based regimens: reversing a pattern of failure. Oncologist 2003;8:350-360.
54. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. The Department of Veterans Affairs Laryngeal Cancer Study Group. N Engl J Med 1991;324:1685-1690.
55. Lefebvre JL, Chevalier D, Luboinski B, et al. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst 1996;88:890-899.
56. Richard JM, Sancho-Garnier H, Pessey JJ, et al. Randomized trial of induction chemotherapy in larynx carcinoma. Oral Oncol 1998;34:224-228.
57. Lefebvre JL, Wolf G, Luboinski B, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC) (2) larynx preservation using neoadjuvant chemotherapy (CT) in laryngeal and hypopharyngeal carcinoma (Abstr). Proc Am Soc Clin Oncol 1998;17:A1473.
58. Bonner JA, Giralt J, Harari PM, et al. Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: A phase III study of high dose radiation therapy with or without cetuximab (Abstr). Proc Am Soc Clin Oncol 2004;22:A5507.
59. Urba SG, Moon J, Giri PG, et al. Organ preservation for advanced resectable cancer of the base of tongue and hypopharynx: a Southwest Oncology Group Trial. J Clin Oncol 2005;23:88-95.
60. Hainsworth JD, Meluch AA, McClurkan S, et al. Induction paclitaxel, carboplatin, and infusional 5-FU followed by concurrent radiation therapy and weekly paclitaxel/carboplatin in the treatment of locally advanced head and neck cancer: a phase II trial of the Minnie Pearl Cancer Research Network. Cancer J 2002;8:311-321.
61. Spaulding MB, Fischer SG, Wolf GT. Tumor response, toxicity, and survival after neoadjuvant organ-preserving chemotherapy for advanced laryngeal carcinoma. The Department of Veterans Affairs Cooperative Laryngeal Cancer Study Group. J Clin Oncol 1994;12:1592-1599.